SV Health Investors Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

SV Health Investors participated in OMass Therapeutics' $310 million Series C financing, co-led by Bain Capital Life Sciences, Forbion and Novo Holdings. SV's Ali Jazayeri received a Board observer seat.

OMass Therapeutics

OMass Therapeutics SV Health Investors

svhealthinvestors.comOCT 15, 2026

SV Health Investors | Activity | F4

OCT 15, 2026

Exit

Portfolio company TRexBio (TRXB) priced its IPO of 8.3M shares at $14.00, raising ~$116.7M, and began trading on the Nasdaq.

TRexBio

TRexBio SV Health Investors

svhealthinvestors.comOCT 9, 2026

OCT 9, 2026

Milestone

Cerevance, an SV Health Investors Dementia Discovery Fund-backed company, announced positive Phase 3 ARISE results for solengepras, a first-in-class non-dopaminergic oral treatment for Parkinson's disease, meeting its primary endpoint with statistically significant motor and non-motor benefits.

Cerevance

Cerevance SV Health Investors

svhealthinvestors.comOCT 7, 2026

OCT 7, 2026

Milestone

Portfolio company Alchemab Therapeutics secured the British Business Bank's largest-ever life sciences investment to advance its AI-enabled antibody pipeline.

Alchemab Therapeutics

Alchemab Therapeutics SV Health Investors

svhealthinvestors.comJUL 9, 2026

JUL 9, 2026

Team Change

Director of Investor Relations Dylan Arpey departed SV Health Investors to lead investor relations and capital formation at Aqualis Partners.

Dylan Arpey departs SV Health

SV Health Investors

briefglance.comMAY 2026

MAY 2026

Investment

Acquired EpiVax, Inc., a bioanalytical CRO specializing in immunogenicity risk assessment, as a new platform investment.

EpiVax

EpiVax SV Health Investors

svhealthinvestors.comAPR 2, 2026

APR 2, 2026

Milestone

Portfolio company Perfuze received FDA clearance for Millipede88, the first super-bore aspiration catheter cleared for standalone direct aspiration.

Perfuze

Perfuze SV Health Investors

svhealthinvestors.comMAR 17, 2026

MAR 17, 2026

Exit

Portfolio company Pivot Point Consulting was acquired by Innovative Consulting Group, forming a unified healthcare IT company.

Pivot Point Consulting

Pivot Point Consulting SV Health Investors

svhealthinvestors.comFEB 17, 2026

FEB 17, 2026

News

Three SV-created biotech companies were named to The Times 100 Tech Ones to Watch list.

The Times 100 Tech Ones to Watch

SV Health Investors

svhealthinvestors.comJAN 16, 2026

JAN 16, 2026

Investment

SV Health Investors participated as an existing investor in HPS/PayMedix's $33 million equity and debt financing round led by HLM Investment Partners.

HPS/PayMedix

HPS/PayMedix SV Health Investors

svhealthinvestors.comJAN 13, 2026

JAN 13, 2026

Team Change

Hired Miles Gerson, formerly Head of Takeda Ventures, as Partner to co-lead the Dementia Discovery Funds and expand US investment activity.

Miles Gerson joined as Partner

SV Health Investors

svhealthinvestors.comJAN 9, 2026

JAN 9, 2026

Investment

SV Health Investors co-founded Draig Therapeutics, which launched from stealth with $140M total investment including a Series A led by Access Biotechnology. The clinical-stage company targets neuropsychiatric disorders.

Draig Therapeutics

Draig Therapeutics SV Health Investors

svhealthinvestors.comJUN 18, 2025

JUN 18, 2025

New Fund

The Dementia Discovery Fund closed DDF-2 at $269M, backed by major pharma LPs and nonprofits, to invest in novel dementia therapeutics.

Dementia Discovery Fund 2 (DDF-2)

SV Health Investors

svhealthinvestors.comMAY 20, 2025

MAY 20, 2025